APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Annexure enclosed12-02-2024
Apollo Hospitals Enterprise Q3 FY24 Results Live : profit rise by 59.85% YOY
Apollo Hospitals Enterprise Q3 FY24 Results Live : Revenue increased by 13.77% YoY & profit increased by 59.85% YoY10-02-2024
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
as per annexure enclosed09-02-2024
Apollo Hospitals Aiming For 70% Occupancy In Next Four Quarters, Says Group CFO
The hospital's average revenue per occupied bed was up 9.5% year-on-year to Rs 56,000, Krishnan Akhileswaran said.09-02-2024
Apollo Hospitals Enterprise Results Earnings Call for Q3FY24
Conference Call with Apollo Hospitals Enterprise Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.09-02-2024
Q3FY24 Quarterly& 9MFY24 Result Announced for Apollo Hospitals Enterprise Ltd.
Healthcare Facilities company Apollo Hospitals Enterprise announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Revenues at Rs 48,506 million vs Rs 42,636 million in Q3FY23; growth of 14% YoY EBITDA at Rs 6,137 million vs Rs 5,053 million in Q3FY23. This is after Apollo 247 cost of Rs 1,557 million in the quarter (including Rs 141 million non-cash ESOP charge) vs Rs 2,024 million in Q3 FY23. Reported PAT at Rs 2,453 million vs Rs 1,535 million in Q3FY23 Diluted EPS of Rs 17.06 per share in Q3FY24 (not annualized) Consolidated 9MFY24: Revenue at Rs 141,153 million vs Rs123,103 million in 9MFY24; growth of 15% YoY EBITDA at Rs 17,502 million vs Rs 15,615 million in 9MFY23. This is after Apollo 247 cost of Rs 5,569 million for 9M(including Rs 785 million non-cash ESOP charge) vs Rs 5,181 million in 9MFY23. PAT stood at Rs 6,448 million vs Rs 5,315 million in 9MFY23 Reported PAT stood at Rs 6,448 million vs Rs 6,746 million in 9MFY23 Diluted EPS of Rs 44.84 per share in 9MFY24 Health Care service Q3FY24 Performance: Revenue at Rs 24,635 million vs Rs 21,944 million in Q3 FY23; growth of 12% YoY EBITDA grew by 8% at Rs 5,860 million vs Rs 5,428 million in Q3FY23; Margins at 23.8% in Q3FY24 PAT stood at Rs 2,872 million vs Rs 2,609 million in Q3FY23, 10% growth Health Care service 9MFY24 Performance: Revenue at Rs 73,044 million vs Rs 64,823 million in 9MFY23; growth of 13% YoY EBITDA grew by 10% at Rs 17,627 million vs Rs 15,984 million in 9MFY23; Margins at 24.1% in 9MFY24 PAT stood at Rs 8,648 million vs Rs 9,043 million in 9MFY23 Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, "In the pursuit of a healthier nation, Apollo remains steadfast in its belief in the importance of preventive healthcare. Our mission is to empower individuals to safeguard their well-being, preventing the onset of NonCommunicable Diseases (NCDs). In a country where 5.8 million lives are claimed annually by NCDs, and 1 in 4 Indians faces the risk of such an outcome before the age of 70, Apollo ProHealth emerges as a beacon of comprehensive personalized prevention. Combining medical expertise with Artificial Intelligence, this program, curated by skilled physicians, evaluates overall health, predicts risks, and guides individuals on a personalized path to wellness. It equips you with the tools and knowledge to make proactive choices for your well-being. Our vision is resolute – to integrate preventive healthcare into the lives of every Indian. More than a business objective, it's a commitment to our nation's health. Together, let's strive to nurture countless healthy and happy families, shielding them from the growing threat of noncommunicable diseases.” Result PDF09-02-2024
Apollo Hospital's pharmacy business to touch 10,000 crore in revenue this year
With 5,790 pharmacies, Apollo is the largest pharmacy chain in India, adding 400-500 stores each year.09-02-2024
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
As per annexure enclosed08-02-2024
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Investor Presentation
As per annexure enclosed08-02-2024